Breyanzi (lisocabtagene maraleucel), new Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene…
XALKORI (CRIZOTINIB) approved for ALK-POSITIVE anaplastic large cell LYMPHOMA in children and young adults
The FDA has approved the supplemental New Drug Application (sNDA) for XALKORI®…